Pegunigalsidase alfa, a PEGylated α-galactosidase A enzyme replacement therapy (ERT) for Fabry disease, has a longer plasma half-life than other ERTs administered intravenously every 2 weeks (E2W). BRIGHT (NCT03180840) was a phase III, open-label study in adults with Fabry disease, previously treated with agalsidase alfa or beta E2W for ≥3 years, who switched to 2 mg/kg pegunigalsidase alfa every 4 weeks (E4W) for 52 weeks. Primary objective assessed safety, including number of treatment-emergent adverse events (TEAEs). Thirty patients were enrolled (24 males); 23 previously received agalsidase beta. Pegunigalsidase alfa plasma concentrations remained above the lower limit of quantification throughout the 4-week dosing interval. Thirty-three of 182 TEAEs (in 9 patients) were considered treatment-related; all were mild/moderate. No patients developed de novo anti-drug antibodies (ADAs). In the efficacy analysis (n = 29), median (inter-quartile range) eGFR change from baseline over 52 weeks was -1.9 (-5.9; 1.8) mL/min/1.73 m2 (n = 28; males [n = 22]: -2.4 [-5.2; 3.2]; females [n = 6]: -0.7 [-9.2; 2.0]). Overall, median eGFR slope was -1.9 (-8.3; 1.9) mL/min/1.73 m2/year (ADA-negative [n = 20]: -1.2 [-6.4; 2.6]; ADA-positive [n = 9]: -8.4 [-11.6; -1.0]). Lyso-Gb3 concentrations were low and stable in females, with a slight increase in males (9/24 ADA-positive). The BRIGHT study results suggest that 2 mg/kg pegunigalsidase alfa E4W is tolerated well in stable adult patients with Fabry disease. Due to the low number of patients in this study, more research is needed to demonstrate the effects of pegunigalsidase alfa given E4W. Further evidence, outside of this clinical trial, should be factored in for physicians to prolong the biweekly ERT intervals to E4W. TAKE-HOME MESSAGE: Treatment with 2 mg/kg pegunigalsidase alfa every 4 weeks could offer a new treatment option for patients with Fabry disease.

Antwerp University Hospital UZA Edegem Belgium

Charles University General University Hospital Prague Czech Republic

Chiesi Farmaceutici S p A Parma Italy

DataSights Ltd Haifa Israel

Department of Endocrinology and Metabolism Rigshospitalet and Faculty of Health and Clinical Sciences Copenhagen University Copenhagen Denmark

Department of Human Genetics Emory University School of Medicine Atlanta Georgia USA

Department of Product Development Protalix Biotherapeutics Carmiel Israel

Department of Public Health University Federico 2 of Naples Naples Italy

Division of Medical Genetics and Genomics Stead Family Department of Pediatrics University of Iowa Iowa City Iowa USA

LSDU Royal Free London NHS Foundation Trust and University College London London UK

Lysosomal and Rare Disorders Research and Treatment Center Fairfax Virginia USA

Lysosomal Disorders Unit Cambridge University Hospitals NHS Foundation Trust and University of Cambridge Cambridge UK

Pediatrics Medical Genetics University of Utah Salt Lake City Utah USA

University of Alabama at Birmingham Birmingham Alabama USA

University of Bergen and Haukeland University Hospital Bergen Norway

University of Sunderland Sunderland UK

Zobrazit více v PubMed

Mehta A, Hughes DA. Fabry disease. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. GeneReviews(®). University of Washington; 2002. (updated March 9, 2023).

National Institutes of Health . Fabry disease. 2022. https://medlineplus.gov/genetics/condition/fabry-disease/#frequency Accessed December 12, 2023.

Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. doi:10.1186/1750-1172-5-30 PubMed DOI PMC

Wanner C, Arad M, Baron R, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189‐203. doi:10.1016/j.ymgme.2018.06.004 PubMed DOI

Azevedo O, Gago MF, Miltenberger‐Miltenyi G, Sousa N, Cunha D. Fabry disease therapy: state‐of‐the‐art and current challenges. Int J Mol Sci. 2020;22(1):206. doi:10.3390/ijms22010206 PubMed DOI PMC

Germain DP, Charrow J, Desnick RJ, et al. Ten‐year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353‐358. doi:10.1136/jmedgenet-2014-102797 PubMed DOI PMC

Germain DP, Waldek S, Banikazemi M, et al. Sustained, long‐term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18(5):1547‐1557. doi:10.1681/asn.2006080816 PubMed DOI

Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743‐2749. doi:10.1001/jama.285.21.2743 PubMed DOI

Genzyme Corporation . Fabrazyme (agalsidase beta) for injection, for intravenous use: prescribing information. 2021.

Shire Human Genetic Therapies AB . Replagal: summary of product characteristics. 2022.

Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18‐month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288‐296. doi:10.1136/jmedgenet-2016-104178 PubMed DOI PMC

Chiesi USA, Inc . Elfabrio (pegunigalsidase alfa‐iwxj) injection, for intravenous use: prescribing information. 2023.

Chiesi Farmaceutici S.p.A . Elfabrio: summary of product characteristics. 2023.

Kizhner T, Azulay Y, Hainrichson M, et al. Characterization of a chemically modified plant cell culture expressed human α‐galactosidase A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015;114(2):259‐267. doi:10.1016/j.ymgme.2014.08.002 PubMed DOI

Schiffmann R, Goker‐Alpan O, Holida M, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease provides sustained plasma concentrations and favorable pharmacodynamics: a 1‐year phase I/II clinical trial. J Inherit Metab Dis. 2019;42(3):534‐544. doi:10.1002/jimd.12080 PubMed DOI

Lenders M, Pollmann S, Terlinden M, Brand E. Pre‐existing anti‐drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa. Mol Ther Methods Clin Dev. 2022;26:323‐330. doi:10.1016/j.omtm.2022.07.009 PubMed DOI PMC

Hughes D, Gonzalez D, Maegawa G, et al. Long‐term safety and efficacy of pegunigalsidase alfa: a multicenter 6‐year study in adult patients with Fabry disease. Genet Med. 2023;25:100968. doi:10.1016/j.gim.2023.100968 PubMed DOI

Linhart A, Dostálová G, Nicholls K, et al. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase III open‐label study. Orphanet J Rare Dis. 2023;18(1):332. doi:10.1186/s13023-023-02937-6 PubMed DOI PMC

Wallace EL, Goker‐Alpan O, Wilcox WR, et al. Head‐to‐head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2‐year randomised phase III BALANCE study. J Med Genet. 2023;61:530. doi:10.1136/jmg-2023-109445 PubMed DOI PMC

Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604‐612. doi:10.7326/0003-4819-150-9-200905050-00006 PubMed DOI PMC

Kidney disease: improving global outcomes (KDIGO). KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012;2:337‐405.

National Cancer Institute . Common terminology criteria for adverse events (CTCAE). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm Accessed December 12, 2023.

U.S. Food and Drug Administration . Immunogenicity testing of therapeutic protein products—developing and validating assays for anti‐drug antibody detection, guidance for industry. 2019.

European Medicines Agency . Guideline on immunogenicity assessment of therapeutic proteins. 2017.

Beck M. The Mainz severity score index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease. Acta Paediatr Suppl. 2006;95(451):43‐46. doi:10.1080/08035320600618825 PubMed DOI

Whybra C, Kampmann C, Krummenauer F, et al. The Mainz severity score index: a new instrument for quantifying the Anderson‐Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65(4):299‐307. doi:10.1111/j.1399-0004.2004.00219.x PubMed DOI

Cleeland CS. Brief Pain Inventory Short Form (BPI‐SF). 1991. https://www.mdanderson.org/documents/Departments‐and‐Divisions/Symptom‐Research/BPI_UserGuide.pdf Accessed December 12, 2023.

EuroQol Research Foundation . EQ‐5D‐5L user guide. 2019. https://euroqol.org/publications/user-guides/ Accessed December 12, 2023.

Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs. 2006;15(6):330‐333. doi:10.12968/bjon.2006.15.6.20681 PubMed DOI

Bashorum L, McCaughey G, Evans O, Humphries AC, Perry R, MacCulloch A. Burden associated with Fabry disease and its treatment in 12–15 year olds: results from a European survey. Orphanet J Rare Dis. 2022;17(1):266. doi:10.1186/s13023-022-02417-3 PubMed DOI PMC

Arends M, Biegstraaten M, Wanner C, et al. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet. 2018;55(5):351‐358. doi:10.1136/jmedgenet-2017-104863 PubMed DOI PMC

van der Veen SJ, Vlietstra WJ, van Dussen L, et al. Predicting the development of anti‐drug antibodies against recombinant α‐galactosidase A in male patients with classical Fabry disease. Int J Mol Sci. 2020;21(16):5784. doi:10.3390/ijms21165784 PubMed DOI PMC

Wang J, Lozier J, Johnson G, et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention, and treatment. Nat Biotechnol. 2008;26(8):901‐908. doi:10.1038/nbt.1484 PubMed DOI PMC

Lenders M, Brand E. Mechanisms of neutralizing anti‐drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in Fabry disease. Drugs. 2021;81(17):1969‐1981. doi:10.1007/s40265-021-01621-y PubMed DOI PMC

van der Veen SJ, Langeveld M. Antibodies against recombinant enzyme in the treatment of Fabry disease: now you see them, now you don't. Mol Ther Methods Clin Dev. 2022;27:324‐326. doi:10.1016/j.omtm.2022.10.007 PubMed DOI PMC

West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol. 2009;20(5):1132‐1139. doi:10.1681/asn.2008080870 PubMed DOI PMC

Carnicer‐Cáceres C, Arranz‐Amo JA, Cea‐Arestin C, et al. Biomarkers in Fabry disease. Implications for clinical diagnosis and follow‐up. J Clin Med. 2021;10(8):1664. doi:10.3390/jcm10081664 PubMed DOI PMC

Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545‐555. doi:10.1056/NEJMoa1510198 PubMed DOI

Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma lyso‐Gb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120(1–2):57‐61. doi:10.1016/j.ymgme.2016.10.006 PubMed DOI

Rombach SM, Dekker N, Bouwman MG, et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta. 2010;1802(9):741‐748. doi:10.1016/j.bbadis.2010.05.003 PubMed DOI

van Breemen MJ, Rombach SM, Dekker N, et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta. 2011;1812(1):70‐76. doi:10.1016/j.bbadis.2010.09.007 PubMed DOI

Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R. Effects of enzyme replacement therapy on pain and health‐related quality of life in patients with Fabry disease: data from FOS (Fabry outcome survey). J Med Genet. 2005;42(3):247‐252. doi:10.1136/jmg.2004.025791 PubMed DOI PMC

Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long‐term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2006;21(2):345‐354. doi:10.1093/ndt/gfi152 PubMed DOI

Weidemann F, Niemann M, Störk S, et al. Long‐term outcome of enzyme replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274(4):331‐341. doi:10.1111/joim.12077 PubMed DOI PMC

Meregaglia M, Nicod E, Drummond M. The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review. Eur J Health Econ. 2022;24:1151‐1216. doi:10.1007/s10198-022-01541-y PubMed DOI PMC

Ramaswami U, Stull DE, Parini R, et al. Measuring patient experiences in Fabry disease: validation of the Fabry‐specific pediatric health and pain questionnaire (FPHPQ). Health Qual Life Outcomes. 2012;10:116. doi:10.1186/1477-7525-10-116 PubMed DOI PMC